Back to search

Netherlands· NL-f392fa51ad3f

OLIMEL N9, emulsie voor infusie

A lösungen zur parenteralen ernährung, kombinationen product containing alanine, (l-) + alanine, (l-) + arginine, (l-) + arginine, (l-), registered in Netherlands by Baxter B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC B05BA10

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedOLIMEL N9, emulsie voor infusieATCB05BA10REGISTER NO.NL-f392fa51ad3fPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Lösungen zur parenteralen ernährung, kombinationen is registered in 11 of 19 countries.

Countries holding a registration under ATC B05BA10 (lösungen zur parenteralen ernährung, kombinationen), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose

Lösungen zur parenteralen ernährung, kombinationen · ATC B05BA10

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ALANINE, (L-) + ALANINE, (L-) + ARGININE, (L-) + ARGININE, (L-)
Manufacturer
Baxter B.V.
Country
Netherlands (NL)
ATC code
B05BA10
ATC class
Lösungen zur parenteralen Ernährung, Kombinationen
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    105718

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

6 interactions on record for lösungen zur parenteralen ernährung, kombinationen.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Lösungen zur parenteralen ernährung, kombinationen · interactions on record

6 records

  • 2 severe
  • 4 moderate

Most severe, free to view

  • ErdafitinibL01EN01severe
  • ErdafitinibL01EX16severe
  • AmfetamineN06BA01moderate
  • DexamfetamineN06BA02moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cfdf6e75-e785-4329-9287-be3fcdfea28d
GET /v1/drugs/cfdf6e75-e785-4329-9287-be3fcdfea28d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Emulsie voor infusie",
  "route": "Intraveneus gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h105718_smpc.pdf",
  "strength": null,
  "atc_label": "Combinations",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg105718",
  "excipients": [
    "ACETAAT  (C2H3O2-)",
    "AZIJNZUUR (E 260), GECONCENTREERD",
    "AZIJNZUUR (E 260), GECONCENTREERD",
    "EI FOSFATIDEN, GEZUIVERD",
    "EI FOSFATIDEN, GEZUIVERD",
    "FOSFAAT (3-)",
    "GLYCEROL (E 422)",
    "GLYCEROL (E 422)",
    "NATRIUMHYDROXIDE (E 524)",
    "NATRIUMHYDROXIDE (E 524)",
    "NATRIUMOLEAAT (E 470A)",
    "NATRIUMOLEAAT (E 470A)",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "WATER VOOR INJECTIE",
    "WATER VOOR INJECTIE",
    "WATER VOOR INJECTIE",
    "WATER VOOR INJECTIE",
    "ZOUTZUUR (E 507)",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "ALANINE, (L-)",
    "ALANINE, (L-)",
    "ARGININE, (L-)",
    "ARGININE, (L-)",
    "ASPARAGINEZUUR, (L-)",
    "ASPARAGINEZUUR, (L-)",
    "FENYLALANINE, (L-)",
    "FENYLALANINE, (L-)",
    "GLUCOSE 1-WATER",
    "GLUCOSE 1-WATER",
    "GLUTAMINEZUUR (L-) (+) (E 620)",
    "GLUTAMINEZUUR (L-) (+) (E 620)",
    "GLYCINE (E 640)",
    "GLYCINE (E 640)",
    "HISTIDINE, (L-)",
    "HISTIDINE, (L-)",
    "ISOLEUCINE, (L-)",
    "ISOLEUCINE, (L-)",
    "LEUCINE, (L-) (E 641)",
    "LEUCINE, (L-) (E 641)",
    "LYSINEACETAAT, L-",
    "LYSINEACETAAT, L-",
    "METHIONINE, (L-)",
    "METHIONINE, (L-)",
    "OLIJFOLIE, GEZUIVERD",
    "OLIJFOLIE, GEZUIVERD",
    "PROLINE, (L-)",
    "PROLINE, (L-)",
    "SERINE, (L-)",
    "SERINE, (L-)",
    "SOJAOLIE, GEZUIVERD",
    "SOJAOLIE, GEZUIVERD",
    "THREONINE, (L-)",
    "THREONINE, (L-)",
    "TRYPTOFAAN, (L-)",
    "TRYPTOFAAN, (L-)",
    "TYROSINE, (L-)",
    "TYROSINE, (L-)",
    "VALINE, (L-)",
    "VALINE, (L-)"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h105718.pdf",
  "authorised_at": "2010/07/27",
  "procedure_number": "FR/H/0419/006",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "105718",
  "additional_monitoring": "N"
}

See everything about lösungen zur parenteralen ernährung, kombinationen.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.